Equillium Receives Australian Approval for EQ504 Phase 1 Trial

Equillium, Inc. announced it has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia for its Phase 1 clinical trial of EQ504. The company expects to begin dosing healthy participants by early November 2026. The Phase 1 trial is a randomized, double-blinded, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EQ504. It includes single ascending dose, multiple ascending dose with GI biopsies, and food effect cohorts.